Key Takeaways
- • APG commits $400 million to China Life Science Infrastructure Venture (CLSIV), a $1.5 billion joint venture with Singapore-based CBC Group targeting Asia Pacific life science real estate, with APG holding an 80% stake and CBC holding 20%.
- • Initial deployment underway in Shanghai with one million square metres (10.8 million square feet) of life science facilities already secured, with expansion planned across nine mainland China cities including Beijing.
- • Dual-platform structure includes CLSIV as the investment vehicle and CBC Healthcare Infrastructure Platform (CBC HIP) as the operating entity responsible for developing and managing healthcare and life science projects across the region.
- • CBC HIP positioned as integrated solution provider offering one-stop infrastructure services to life science companies, enabling them to focus on R&D while outsourcing facility management and development.
- • First closing completed with CBC contributing $100 million alongside APG's $400 million commitment, establishing a $500 million initial capital base with significant dry powder for additional deployment.
Summary
APG Asset Management, the Dutch pension fund manager with €610 billion in assets under management, has entered a strategic partnership with CBC Group, a Singapore-based healthcare investment firm, to capitalize on growing demand for specialized real estate in Asia Pacific's life sciences sector. The partners have established a $1.5 billion venture comprising two entities: China Life Science Infrastructure Venture (CLSIV), the investment vehicle, and CBC Healthcare Infrastructure Platform (CBC HIP), the operational arm responsible for project development and management.
In the venture's first closing, APG committed $400 million while CBC contributed $100 million, establishing a $500 million initial capital base and creating an 80/20 ownership split in favor of APG. The partnership reflects growing institutional investor appetite for real estate backing high-growth biotech and pharmaceutical sectors, particularly in China's emerging life sciences hubs. According to CBC HIP chief executive officer Hans Kang, the platform aims to provide "integrated one-stop solution to all kinds of facility requirements on these life science companies, so that they can focus on their R&D activities and main businesses."
The venture is launching with Shanghai as its primary hub, where it has already secured a one-million-square-metre pipeline of life science facilities. Expansion is planned across nine mainland China cities, with Beijing identified as an additional near-term opportunity. By positioning itself as the first-mover infrastructure provider for life science companies in China, the platform addresses a structural gap in supply of purpose-built facilities for research and development operations.
This investment aligns with APG's broader European and institutional real estate strategy, building on prior acquisitions such as the Alba-Bra hospital in Verduno, Italy, acquired in 2019. The $1.5 billion fund size signals significant confidence in the durability and scale of the Asia Pacific life sciences real estate market, with substantial dry powder remaining for deployment beyond the initial Shanghai and Beijing projects.
In the venture's first closing, APG committed $400 million while CBC contributed $100 million, establishing a $500 million initial capital base and creating an 80/20 ownership split in favor of APG. The partnership reflects growing institutional investor appetite for real estate backing high-growth biotech and pharmaceutical sectors, particularly in China's emerging life sciences hubs. According to CBC HIP chief executive officer Hans Kang, the platform aims to provide "integrated one-stop solution to all kinds of facility requirements on these life science companies, so that they can focus on their R&D activities and main businesses."
The venture is launching with Shanghai as its primary hub, where it has already secured a one-million-square-metre pipeline of life science facilities. Expansion is planned across nine mainland China cities, with Beijing identified as an additional near-term opportunity. By positioning itself as the first-mover infrastructure provider for life science companies in China, the platform addresses a structural gap in supply of purpose-built facilities for research and development operations.
This investment aligns with APG's broader European and institutional real estate strategy, building on prior acquisitions such as the Alba-Bra hospital in Verduno, Italy, acquired in 2019. The $1.5 billion fund size signals significant confidence in the durability and scale of the Asia Pacific life sciences real estate market, with substantial dry powder remaining for deployment beyond the initial Shanghai and Beijing projects.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.